ArticleFrontiers in pharmacology2026
Pharmacological safety and real-world efficacy of the potassium-competitive acid blocker fexuprazan in cardiovascular patients receiving antithrombotic therapy: a prospective cohort study (FEXGARD).
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Gastroesophageal reflux disease (GERD) is common in patients with CVD receiving long-term antithrombotic therapy, increasing gastrointestinal (GI) bleeding risk. Potassium-competitive acid blockers, such as fexuprazan, provide rapid and potent acid suppression; however, relevant evidence in this high-risk population is limited. This study evaluated the effects of fexuprazan on fasting serum gastrin levels, GERD symptoms, and bleeding outcomes in patients with CVD receiving antithrombotic agents. Methods: In this prospective observational study conducted at a tertiary hospital, 400 patients receiving antiplatelet or anticoagulant therapy were administered fexuprazan. Fasting venous blood samples were collected at baseline and 6 months, and total serum gastrin levels were measured. GERD symptoms were assessed using the Frequency Scale for the Symptoms of GERD (FSSG). Secondary outcomes, including GI bleeding, other-site bleeding, and mortality, were recorded over 12 months. Subgroup analyses were performed according to antithrombotic regimen and age. Results: Fexuprazan significantly increased fasting serum gastrin (152.1 ± 215.9 vs. 249.1 ± 210.3 pg/mL; p < 0.001) and improved FSSG total scores (16.3 ± 5.0 vs. 15.0 ± 6.0; p < 0.001). During the 12 months, two GI bleeding events (0.5%), 11 other-site bleeding events (2.8%), and no deaths occurred. Subgroup analyses revealed no significant differences between users of antiplatelet agents, warfarin, and non-vitamin K antagonist oral anticoagulants (NOACs). However, bleeding events occurred only in the NOAC group. Patients aged 70 years or older had a greater increase in gastrin than younger patients (+118.4 vs. +64.3 pg/mL; p = 0.025). Conclusion: Fexuprazan increased gastrin levels and improved GERD symptoms with few bleeding events in patients with CVD receiving antithrombotic therapy. This study provides clinical data on the safety and tolerability of fexuprazan in a high-risk cardiovascular population under long-term antithrombotic therapy. Elderly patients exhibited a greater increase in gastrin levels, warranting closer monitoring and further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.